Limits...
Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Manceau P, Latarche C, Pittion S, Edan G, de Sèze J, Massart C, Debouverie M - BMC Neurol (2014)

Bottom Line: Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy.Of the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNβ, and 57.4% had a pathological MFIS score.This study demonstrates the impact of NAb on the non-clinical response to IFNβ.

View Article: PubMed Central - PubMed

ABSTRACT

Background: The clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study to assess the association between response to IFNβ, NAb and fatigue.

Methods: Patients with relapsing-remitting MS on IFNβ treatment were included. During the second year of treatment, the patients were analyzed for NAb status and non-response criteria to IFNβ (number of relapses ≥1 during the follow-up period, increase in the Expanded Disability Status Scale ≥0.5). The score on the Modified Fatigue Impact Scale (MFIS pathological if score ≥35) was noted for each patient.

Results: Of the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNβ, and 57.4% had a pathological MFIS score. Fatigue was increased in NAb + patients (p = 0.0014) and they were more likely to present non-response criteria to IFNβ (p = 0.041) than NAb- patients. Multivariate logistic regression analysis showed that the presence of NAb was related to fatigue (p = 0.0032) and denoted disease activity in these patients (p = 0.026).

Conclusions: This study demonstrates the impact of NAb on the non-clinical response to IFNβ. Fatigue assessment is an indicator of IFNβ responsiveness and a predictive biomarker of deterioration on patient's neurological status.

No MeSH data available.


Related in: MedlinePlus

Influence of NAb titer on MFIS score at follow-up consultation. a. NAb titer depending on MFIS score. b. Comparison of mean MFIS score at follow-up consultation between NAb- patients, weak/moderate NAb + patients and strong NAb + patients. *p <0.05, **p <0.01.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4256902&req=5

Fig4: Influence of NAb titer on MFIS score at follow-up consultation. a. NAb titer depending on MFIS score. b. Comparison of mean MFIS score at follow-up consultation between NAb- patients, weak/moderate NAb + patients and strong NAb + patients. *p <0.05, **p <0.01.

Mentions: Among the 39 NAb + patients, the mean NAb titer was 878 +/− 346 TRU/mL. Our study did not reveal any correlation between the NAb titer and MFIS score (Spearman coefficient r = 0.14; p = 0.38) (Figure 4a).Figure 4


Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Manceau P, Latarche C, Pittion S, Edan G, de Sèze J, Massart C, Debouverie M - BMC Neurol (2014)

Influence of NAb titer on MFIS score at follow-up consultation. a. NAb titer depending on MFIS score. b. Comparison of mean MFIS score at follow-up consultation between NAb- patients, weak/moderate NAb + patients and strong NAb + patients. *p <0.05, **p <0.01.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4256902&req=5

Fig4: Influence of NAb titer on MFIS score at follow-up consultation. a. NAb titer depending on MFIS score. b. Comparison of mean MFIS score at follow-up consultation between NAb- patients, weak/moderate NAb + patients and strong NAb + patients. *p <0.05, **p <0.01.
Mentions: Among the 39 NAb + patients, the mean NAb titer was 878 +/− 346 TRU/mL. Our study did not reveal any correlation between the NAb titer and MFIS score (Spearman coefficient r = 0.14; p = 0.38) (Figure 4a).Figure 4

Bottom Line: Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy.Of the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNβ, and 57.4% had a pathological MFIS score.This study demonstrates the impact of NAb on the non-clinical response to IFNβ.

View Article: PubMed Central - PubMed

ABSTRACT

Background: The clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study to assess the association between response to IFNβ, NAb and fatigue.

Methods: Patients with relapsing-remitting MS on IFNβ treatment were included. During the second year of treatment, the patients were analyzed for NAb status and non-response criteria to IFNβ (number of relapses ≥1 during the follow-up period, increase in the Expanded Disability Status Scale ≥0.5). The score on the Modified Fatigue Impact Scale (MFIS pathological if score ≥35) was noted for each patient.

Results: Of the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNβ, and 57.4% had a pathological MFIS score. Fatigue was increased in NAb + patients (p = 0.0014) and they were more likely to present non-response criteria to IFNβ (p = 0.041) than NAb- patients. Multivariate logistic regression analysis showed that the presence of NAb was related to fatigue (p = 0.0032) and denoted disease activity in these patients (p = 0.026).

Conclusions: This study demonstrates the impact of NAb on the non-clinical response to IFNβ. Fatigue assessment is an indicator of IFNβ responsiveness and a predictive biomarker of deterioration on patient's neurological status.

No MeSH data available.


Related in: MedlinePlus